CEDAR KNOLLS, N.J., Dec. 7, 2020 /PRNewswire/ -- MYOS Corp ("MYOS" or the "Company"), formerly known as Myos Rens Technology, is a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, announced today that it has entered into an international distribution agreement with Smart Supplement Ltd. to distribute its YOLKED® sports nutrition products across Hong Kong and neighboring South Asian countries.
"We are very excited to announce our partnership with Smart Supplement, a leading nutritional supplement distributor in Hong Kong. International growth is a key area of focus for MYOS and we are thrilled to be able to find a partner that shares our passion for science and continuous research to improve human health. We look forward to working with Smart Supplement to educate individuals on the importance of muscle health," says MYOS CEO Joseph Mannello.
Smart Supplement was established in 2015, and over the past five years has quickly risen to become one of the most popular platforms in Hong Kong for sports and health supplements. Smart Supplement actively seeks innovative, high-quality health products to present to its customers. CEO Patrick Lian stated, "Individuals who seek to reach their health and fitness goals, like The Smart Supplement team, will indefinitely benefit from this product! It's time to #GetYolked!"
Mr. Lian continued, "Our E-Commerce website has over 1.5 million cumulative users, and we also have two physical stores at the heart of Hong Kong's bustling areas Mong Kok and Causeway Bay. Apart from interacting closely with our customers in-store, we also connect with them and our wider audience online - through Facebook, Instagram, and our website, which has attracted over 10 million cumulative views. Our online orders are shipped to all areas in Hong Kong, and we also ship overseas to customers from other Southeast Asian countries like Taiwan, Singapore, and Malaysia."
About MYOS Corp
MYOS Corp (MYOS), formerly known as Myos Rens Technology Inc., "The Muscle Company ® ", is a Cedar Knolls, NJ -based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin ®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass and reduce muscle atrophy. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness and produces muscle health support products featuring Fortetropin under the names of Yolked®, Physician Muscle Health Formula®, MYOS Canine Muscle Formula®, (Regular & Vet Strength) and Qurr®. For more information, please visit www.myoscorp.com .
Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the success of our products, including Yolked®, Physician Muscle Health Formula®, MYOS Canine Muscle Formula®, Qurr®, and MYOS Enteral Nutrition Formula™, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate revenue and cash flow from sales of our products, the ability to increase our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of adverse economic conditions, including as a result of the COVID-19 pandemic, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.
Investor Relations:
MYOS CORP
Joanne Goodford
Phone: 973-509-0444
Email: [email protected]
SOURCE MYOS Corp
Share this article